These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 2199394)

  • 1. Efficacy of orchiectomy versus high dose polyoestradiol phosphate (160 mg) in relieving infravesical obstruction in patients with prostatic cancer.
    Aro J; Haapiainen R; Rannikko S; Alfthan O
    Int Urol Nephrol; 1990; 22(1):57-60. PubMed ID: 2199394
    [TBL] [Abstract][Full Text] [Related]  

  • 2. High dose polyoestradiol phosphate with and without acetosalicylic acid versus orchiectomy in the treatment of prostatic cancer. Finnprostate Group.
    Aro JL; Haapiainen RK; Rannikko SA; Alfthan OS
    Br J Urol; 1989 May; 63(5):512-4. PubMed ID: 2659136
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of primary orchiectomy and polyoestradiol phosphate in the treatment of advanced prostatic cancer. Finnprostate Group.
    Haapiainen R; Rannikko S; Alfthan O
    Br J Urol; 1990 Jul; 66(1):94-7. PubMed ID: 2132303
    [TBL] [Abstract][Full Text] [Related]  

  • 4. re: Comparison of primary orchiectomy and polyoestradiol phosphate in the treatment of advanced prostatic cancer. R. Haapiainen et al. Br. J. Urol., 66, 94-97, 1990.
    Bishop MC
    Br J Urol; 1991 Aug; 68(2):218. PubMed ID: 1884161
    [No Abstract]   [Full Text] [Related]  

  • 5. Efficacy of silodosin for relieving benign prostatic obstruction: prospective pressure flow study.
    Matsukawa Y; Gotoh M; Komatsu T; Funahashi Y; Sassa N; Hattori R
    J Urol; 2009 Dec; 182(6):2831-5. PubMed ID: 19837428
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy of silodosin for relieving benign prostatic obstruction: prospective pressure flow study.
    Matsukawa Y; Gotoh M; Komatsu T; Funahashi Y; Sassa N; Hattori R
    J Urol; 2013 Jan; 189(1 Suppl):S117-21. PubMed ID: 23234615
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The oestrogenic effects of ethinyl oestradiol/polyoestradiol phosphate and estramustine phosphate in patients with prostatic carcinoma. A comparative study of oestrogen sensitive liver proteins, gonadotrophins and prolactin.
    Daehlin L; Damber JE; von Schoultz B; Bergman B
    Br J Urol; 1986 Aug; 58(4):412-6. PubMed ID: 3092893
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Oestrogen dosage in prostatic cancer: the threshold effect?
    Bishop MC; Lemberger RJ; Selby C; Lawrence WT
    Br J Urol; 1989 Sep; 64(3):290-6. PubMed ID: 2679960
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Deteriorated arterial supply to the lower limb during oral oestrogen therapy of patients with prostatic carcinoma.
    Henriksson P; Linde B
    Urol Int; 1994; 53(2):74-8. PubMed ID: 7801420
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Endocrine therapy for bladder outlet obstruction from carcinoma of the prostate.
    Fleischmann JD; Catalona WJ
    J Urol; 1985 Sep; 134(3):498-500. PubMed ID: 4032546
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Orchiectomy versus oestrogen in the treatment of advanced prostatic cancer.
    Haapiainen R; Rannikko S; Ruutu M; Ala-Opas M; Hansson E; Juusela H; Permi J; Saarialho M; Viitanen J; Alfthan O
    Br J Urol; 1991 Feb; 67(2):184-7. PubMed ID: 2004233
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The development of detrusor instability in prostatic obstruction in relation to sequential changes in voiding dynamics.
    Cucchi A
    J Urol; 1994 May; 151(5):1342-4. PubMed ID: 7512664
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Transurethral thermotherapy for benign prostatic hyperplasia significantly decreases infravesical obstruction: results in 134 patients after 1 year.
    Thalmann GN; Graber SF; Bitton A; Burkhard FC; Gruenig O; Studer UE
    J Urol; 1999 Aug; 162(2):387-93. PubMed ID: 10411044
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Analysis of maximum detrusor contraction power in relation to bladder emptying in patients with lower urinary tract symptoms and benign prostatic enlargement.
    Rosier PF; de Wildt MJ; de la Rosette JJ; Debruyne FM; Wijkstra H
    J Urol; 1995 Dec; 154(6):2137-42. PubMed ID: 7500477
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Urodynamics and safety of the β₃-adrenoceptor agonist mirabegron in males with lower urinary tract symptoms and bladder outlet obstruction.
    Nitti VW; Rosenberg S; Mitcheson DH; He W; Fakhoury A; Martin NE
    J Urol; 2013 Oct; 190(4):1320-7. PubMed ID: 23727415
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Patients at high risk of cardiovascular complications in oestrogen treatment of prostatic cancer.
    Henriksson P; Edhag O; Eriksson A; Johansson SE
    Br J Urol; 1989 Feb; 63(2):186-90. PubMed ID: 2649197
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Experience in treating advanced prostate cancer with bladder outlet obstruction].
    Sheng XJ; Zhu YJ; Ye M; Chen JH; Zhang L; Kong L
    Ai Zheng; 2005 Oct; 24(10):1284-6. PubMed ID: 16219150
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of primary orchiectomy with oestrogen therapy in advanced prostatic cancer. A 2-year follow-up report of a national, prospective prostatic cancer study.
    Haapiainen R; Rannikko S; Alfthan O
    Br J Urol; 1986 Oct; 58(5):528-33. PubMed ID: 3779355
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Transurethral hyperthermia for relieving obstructive voiding symptoms in patients with hormone refractory prostate cancer.
    Nativ O; Mor Y; Leibovitch I; Halachmi S; Goldwasser B
    Isr J Med Sci; 1997 Mar; 33(3):182-5. PubMed ID: 9313787
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Clinical significance of residual urine volume in bladder outlet obstruction with benign prostatic hyperplasia].
    Wu Z; Wu K; Wang B
    Zhonghua Wai Ke Za Zhi; 1997 Jun; 35(6):374-6. PubMed ID: 10374477
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.